The PI3K inhibitor, buparlisib, in combination with the smoothened (SMO) inhibitor, erismodegib, in Hedgehog signaling pathway is currently under investigation for determining the efficacy of the treatment in BCC [166]. This evidence concerns the gene PIK3CA and skin basal cell carcinoma.